Stem cell technology is one of the most promising innovations in the medical field right now. Healthcare researchers are working on regenerative medicine solutions to treat a variety of diseases and chronic conditions. In this article, we’ll discuss the best stem cell stocks on the market right now.
Stem cells are essentially the body’s base cells. Every other type of cell forms from stem cells. Because of this, stem cells could be used to replace damaged cells in the body.
Researchers have been testing stem cell therapies for years as a potential treatment for serious diseases like cancer, diabetes, heart disease, Alzheimer’s disease, Parkinson’s disease, and more.
Additionally, researchers can use stem cells as a safe way to test new drugs before using human patients. Researchers essentially program the cells to become a certain type of tissue that they need to test. This is a relatively new testing method that is still in development.
Wondering where to buy the stocks listed in this article? Check out WeBull! WeBull is a trading app that’s great for both beginners and expert investors. They don’t charge any commission fees and will even give you free stocks just for signing up.
Best Stem Cell Stocks
Integra LifeSciences (NASDAQ: IART)
Integra LifeSciences is a medical technology company based in New Jersey. They focus on regenerative medicine and have a large portfolio of products, including technology and tools for neurosurgery and tissue repair.
The company has been in business since 1989. Their first product was an engineered collagen technology, and they have since built their portfolio entirely around regenerative technologies. They have a global presence, with research facilities and offices on several different continents.
Integra LifeSciences stock has done very well over the last several months. In fact, the stock is currently at its highest price point in five years.
Many companies in the medical field are still struggling as a result of the pandemic, but this doesn’t seem to be the case for Integra LifeSciences. Their most recent earnings report indicates that they are consistently profitable, and their earnings per share increased 20 percent year over year in the second half of 2020.
If you’re interested in stem cell technology and regenerative medicine, this seems to be a stock worth considering. They have a global market presence and have a long history of developing innovative technology. Their financial stability upward trajectory on the stock market is another positive for investors.
Stem Cell Research Stocks
Magenta Therapeutics (NASDAQ: MGTA)
Magenta Therapeutics is an exciting biotech company that’s focused entirely on improving the stem cell transplant process. Right now, only a small percentage of people who could benefit from stem cell transplants actually get them. This is because the process comes with significant risks.
This company is working to make cellular therapies much easier and safer. One of their most exciting products in development would shorten the collection time for stem cell donors. Right now, the process takes several days and isn’t always successful.
However, early trials of their new compound, MGT-145, indicate that it could speed up the process significantly, increase the number of stem cells collected from each donor, and reduce side effects.
This compound is currently in phase 2 trials. If this technology eventually makes it to the market, it would likely be very financially successful for Magenta. This is because MGT-145 doesn’t currently have any direct competitors.
Magenta has other technologies in earlier stages of clinical trials right now. This includes a group of profiles that would remove disease-causing cells safely, and could be a replacement for chemotherapy or radiation. They are also working on solutions for effective stem cell dosing and safe transplant recovery.
This company’s stock has fluctuated over the last year. However, their share price has consistently improved since November 2020.
Investors will want to keep an eye on the clinical trial results for MGT-145. If this promising compound does make it to the market, this stock could see huge returns in the long run.
Stem Cell Stocks To Buy
Vericel Corp. (NASDAQ: VCEL)
Vericel is a biopharmaceutical company that uses stem cells and other regenerative technologies in their products. Right now, their two main products are for burn treatment and sports medicine.
The company’s first product is called MACI, and it treats problems with cartilage in the knee. The knee can be a very unstable joint, and many athletes have ongoing issues with cartilage that are difficult to repair. MACI uses the patients’ own cells to regenerate new, healthy knee cartilage, and has been fully approved by the FDA.
Vericel’s other product is called Epicel, and it is used to treat patients with severe burns. They take two very small biopsies from the patient, and use stem cells to grow large grafts to repair burn damage.
The company also has a product in their pipeline at the moment called Nexabrid. Nexabrid is another product that can treat severe thermal burns.
Vericel stock has steadily gone up over the last several months. The stock hit its highest point ever in mid-February. The data from their most recent earnings report is very positive as well.
The company posted their highest revenue numbers ever in 2020, despite the challenges of the pandemic. Vericel is using stem cell therapies in very unique ways, and they’ve carved out a steady niche in the healthcare market that appears to be successful in the long run.
Vericel also expects increased sales for MACI over the next year as United Healthcare announced extended coverage for the product under their health insurance plans. This will make the product accessible to more customers who can benefit from it.
Gamida Cell Ltd. (NASDAQ: GDMA)
Gamida Cell is an Israeli company that develops treatments for blood cancers and other serious blood disorders. They currently have two products in their pipeline.
The first is Omidubicel, which is designed as a bone marrow transplant solution for people with blood cancer. It has received an orphan drug designation from both the United States and the European Union.
In May 2020, Gamida Cell completed a phase 3 trial for this drug as a treatment for high risk blood cancers. The results were positive, and we can expect to see this product move forward in 2021. There is also a phase 1/2 trial for Omidubicel as a treatment for severe aplastic anemia.
Gamida Cell also has another drug called GDA-201 currently in trials. This drug is designed to treat non-Hodgkin lymphoma as well as multiple myeloma and is currently in phase 1/2 trials.
After the company announced their phase 3 results for Ombudicel, their stock price jumped up dramatically. Shares hit a year-long high point on February 10th, but have since dropped off slightly.
If Ombudicel is approved by the FDA or by governing bodies in Europe, we can expect to see Gamida Cell’s stock price go up again. Investors should keep an eye on the company’s clinical results. However, it’s also important to keep an eye on their financials, as they currently aren’t generating any revenue.
Stem Cell Stocks To Watch
Sangamo Therapeutics (NASDAQ: SGMO)
Sangamo Therapeutics is a biotech company that focuses on gene and cell therapy. They currently have a wide variety of treatments in their pipeline. Many of these treatments are for rare conditions that don’t currently have viable treatments available.
The company currently has a gene therapy treatment for hemophilia in phase 3 of their pipeline, which is a collaboration with Pfizer. They also have treatments for Fabry disease and sickle cell disease in phase 1/2.
Because gene and cellular therapies require extensive research, Sangamo reorganized the company into two separate wings last year. They now have one wing for preclinical research and another one for clinical stage development. Within these two wings, they have four different divisions – gene therapy, cell therapy, genome editing, and genome regulation.
However, there are aspects of each division that are interconnected. Research from each division is approached from a holistic standpoint to maximize innovation.
Sangamo stock rose in December, when Sangamo indicated that they were potentially interested in being acquired. However, their stock price started to dip in 2021 as a result of a less-than-stellar earnings report.
Investors will want to keep an eye on Sangamo’s hemophilia treatment. If it is cleared by the FDA after their stage 3 trial concludes, it could lead to a significant boost in their stock price.
Stem Cell Penny Stocks
Athersys Inc. (NASDAQ: ATHX)
Athersys is a growing biotech company with operations in Cleveland, Ohio and Leuven, Belgium. They are developing a product called MultiStem, which could be used to treat a variety of conditions. These include neurological, cardiovascular, immune, and inflammatory conditions.
There are multiple clinical stage trials running right now for MultiStem, each focusing on different diseases and conditions. The most promising trial is one for ischemic stroke, which is currently in a phase 3 trial in the US, as well as other trials around the world.
There are also clinical trials underway to test MultiStem for acute respiratory distress syndrome associated with COVID-19. This program has been given Fast Track status by the FDA.
On top of that, Athersys is running clinical trials for MultiStem as a treatment for traumatic injuries and acute myocardial infarction. Both of these trials are currently in phase 2. Athersys stock increased significantly when they started the trauma trial in December.
As with all penny stocks, there are some risks that come with investing in Athersys. Penny stocks can be very volatile and fluctuate more often than stocks with a higher price point.
However, Athersys is still developing very exciting technologies that may lead to significant returns in the long run. This is one of the most exciting stem cell companies on the market right now, and is worth considering for investors that are willing to take a risk.
Should You Buy Stem Cell Stocks?
Stem cell stocks have done very well on the market over the last few months. However, they have historically been very volatile, fluctuating up and down as public sentiment changes. Many people are wondering if these stem cell companies are worth investing in in the long run.
Stem cell research is extremely promising. In theory, you could use stem cell therapy to treat a huge range of chronic health conditions. The biggest challenge for stem cell companies has been figuring out how to program these stem cells into the specific types of cells they need.
Regenerative medicine has come a long way over the years. Right now, there are FDA approved treatments available that use stem cells from the umbilical cord to form blood cells and treat the hematopoietic system. There are many other stem cell treatments in development right now that would treat other conditions.
There are also regenerative medicine treatments that use the patient’s own cells, but do not use stem cells. Vericel is an example of a company that does this.
Stem cell stocks tend to fluctuate based on clinical trial results and financial news. As more stem cell therapies are approved by the FDA, their corresponding stocks could go up dramatically in price.
While stem cell treatments are still fairly new, there may come a time where we use stem cells to treat a huge range of conditions. Now is a good time to add stem cell stocks to your portfolio for the long run.
Looking for even more great stocks to invest in? Check out Trade Ideas. Trade Ideas uses an innovative AI-based software to help you find exciting investment opportunities without the hassle.
Stem Cell Stocks: Final Thoughts
Stem cell therapeutics could provide much needed treatments for serious diseases in the near future. Investing in the most innovative stem cell companies now is an easy way to benefit from this exciting medical technology.